Kinnate Biopharma's market cap is currently ―. The company's EPS TTM is $-2.819; its P/E ratio is -0.49; Kinnate Biopharma is scheduled to report earnings on November 9, 2023, and the estimated EPS forecast is $-0.66. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -31.92M	$ -34.65M	$ -32.73M	$ -31.37M	$ -27.41M
EBITDA	$ 0.00	$ -35.19M	$ -32.84M	$ -31.19M	$ -27.23M
Net Income Common Stockholders	$ -31.92M	$ -32.94M	$ -31.61M	$ -30.74M	$ -27.07M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 184.70M	$ 200.98M	$ 227.20M	$ 230.98M	$ 233.00M
Total Assets	$ 216.18M	$ 243.88M	$ 278.83M	$ 302.13M	$ 323.90M
Total Debt	$ 3.70M	$ 3.95M	$ 4.18M	$ 4.42M	$ 4.54M
Net Debt	$ -181.00M	$ -197.03M	$ -223.02M	$ -226.56M	$ -228.46M
Total Liabilities	$ 18.52M	$ 21.12M	$ 20.36M	$ 18.79M	$ 15.17M
Stockholders Equity	$ 197.64M	$ 222.76M	$ 223.47M	$ 248.34M	$ 273.73M
Cash Flow	-
Free Cash Flow	-	$ -27.73M	$ -23.84M	$ -20.72M	$ -24.09M
Operating Cash Flow	-	$ -27.72M	$ -23.75M	$ -20.66M	$ -23.54M
Investing Cash Flow	-	$ 55.42M	$ 17.57M	$ 16.96M	$ 23.28M
Financing Cash Flow	-	$ -9.12M	$ 193.00K	$ 190.00K	$ 652.00K

Currency in USD

Kinnate Biopharma Earnings and Revenue History

Income Statement >

Kinnate Biopharma Debt to Assets

Balance Sheet >

Kinnate Biopharma Cash Flow

Cash Flow >

Kinnate Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing